全文获取类型
收费全文 | 126871篇 |
免费 | 9628篇 |
国内免费 | 3605篇 |
专业分类
耳鼻咽喉 | 1009篇 |
儿科学 | 2369篇 |
妇产科学 | 1807篇 |
基础医学 | 7255篇 |
口腔科学 | 2902篇 |
临床医学 | 15342篇 |
内科学 | 19036篇 |
皮肤病学 | 2307篇 |
神经病学 | 6518篇 |
特种医学 | 4254篇 |
外国民族医学 | 39篇 |
外科学 | 12585篇 |
综合类 | 18384篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5328篇 |
眼科学 | 2056篇 |
药学 | 10218篇 |
74篇 | |
中国医学 | 11024篇 |
肿瘤学 | 17572篇 |
出版年
2024年 | 308篇 |
2023年 | 2264篇 |
2022年 | 4152篇 |
2021年 | 5604篇 |
2020年 | 5251篇 |
2019年 | 4690篇 |
2018年 | 4445篇 |
2017年 | 4897篇 |
2016年 | 5206篇 |
2015年 | 4998篇 |
2014年 | 9036篇 |
2013年 | 11428篇 |
2012年 | 7401篇 |
2011年 | 7893篇 |
2010年 | 6511篇 |
2009年 | 5999篇 |
2008年 | 5876篇 |
2007年 | 6295篇 |
2006年 | 5633篇 |
2005年 | 4998篇 |
2004年 | 4053篇 |
2003年 | 3670篇 |
2002年 | 3004篇 |
2001年 | 2656篇 |
2000年 | 2204篇 |
1999年 | 1726篇 |
1998年 | 1438篇 |
1997年 | 1215篇 |
1996年 | 998篇 |
1995年 | 906篇 |
1994年 | 714篇 |
1993年 | 557篇 |
1992年 | 497篇 |
1991年 | 450篇 |
1990年 | 390篇 |
1989年 | 342篇 |
1988年 | 331篇 |
1987年 | 281篇 |
1986年 | 225篇 |
1985年 | 264篇 |
1984年 | 230篇 |
1983年 | 170篇 |
1982年 | 175篇 |
1981年 | 174篇 |
1980年 | 133篇 |
1979年 | 128篇 |
1978年 | 67篇 |
1977年 | 46篇 |
1976年 | 52篇 |
1975年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
《Survey of ophthalmology》2023,68(5):940-956
Congenital aniridia is a panocular disorder that is typically characterized by iris hypoplasia and aniridia-associated keratopathy (AAK). AAK results in the progressive loss of corneal transparency and thereby loss of vision. Currently, there is no approved therapy to delay or prevent its progression, and clinical management is challenging because of phenotypic variability and high risk of complications after interventions; however, new insights into the molecular pathogenesis of AAK may help improve its management. Here, we review the current understanding about the pathogenesis and management of AAK. We highlight the biological mechanisms involved in AAK development with the aim to develop future treatment options, including surgical, pharmacological, cell therapies, and gene therapies. 相似文献
13.
14.
Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder. 相似文献
15.
16.
17.
18.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
19.
20.